Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Tesofensine (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms Viking
  • Sponsors Medix
  • Most Recent Events

    • 17 Dec 2018 Primary endpoint has been met. (An absolute and percent change in body weight over the treatment period), according to a Saniona media release.
    • 17 Dec 2018 Results presented in a Saniona media release.
    • 14 Nov 2018 According to a Saniona media release, Sanionas partner Medix has initiated the data-lock procedure for this study after the last patient has completed the 3-month follow-up visit.Top-line results are expected to be available in Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top